본문 바로가기
KERD
논문KCI 등재

Interest group influence over drug pricing policy reform in South Korea

정우진|김한중
연세대학교의과대학 (Yonsei University College of Medicine)|2005.06|Yonsei Medical Journal|제46권 제3호|pp. 321-330

1

조회

0

다운로드

0

인용

0

참고문헌

주제분류의학일반

초록

Abstract

In 1999, the Korean government made a drug pricing policy reform to improve the efficiency and transparency of the drug distribution system. Yet, its policy formation process was far from being rational. Facing harsh resistance from various interest groups, the government changed its details into something different from what was initially investigated and planned. So far, little evidence supports any improvement in Korea's drug distribution system. Instead, the new drug pricing policy has deteriorated Korea's national health insurance budget, indicating a heavier economic burden for the general public. From Korea's experience, we may draw some lessons for the future development of a better health care system. As a society becomes more pluralistic, the government should come out of authoritarianism and thoroughly prepare in advance for resistance to reform, by making greater efforts to persuade strong interest groups while informing the general public of potential benefits of the reform. Additionally, facing developing civic groups, the government should listen but not rely too much on them at the final stage of the policy formation. Many of the civic groups lack expertise to evaluate the details of policy and tend to act in a somewhat emotional way.

참고문헌 (35)

  1. "Korean doctors end crippling strike", 356, pp.54~ (2000)
  2. "A challenge for reform in South Korea", 42, pp.152~3 (2001)
  3. "Doctors' first strike in Republic of Korea likely to end", 78, pp.1478~ (2000)
  4. "Pharmaceutical reform and physician strike in Korea separation of drug prescribing and dispensing", 57, pp.529~38 (2003)
  5. "Lessons from Korea's pharmaceutical policy reform the separation of medical institutions and pharmacies for outpatient care", 68, pp.267~75 (2004)
  6. "Health policymaking in the United States" (1998), Health Administration Press
  7. "Physicians' conflicts of interest in Japan and the United States Lessons for the United States", 25, pp.343~75 (2000)
  8. "Power to the people Restoring citizen participation", 28, pp.271~88 (2003)
  9. "Policy measures for pharmaceutical industry in the 21st century" (1997), Korea Pharmaceutical Manufacturers Association. Unpublished document,
  10. "Korea Ministry of Health and Welfare Report on policy measures for improving drug reimbursement pricing policy Korea Ministry of Health and Welfare" (1999), Unpublished document
  11. "Research Institute for Health Policy and Management Developing the resource-based relative value system in Korea" (1997), Yonsei University
  12. "Korea Ministry of Health and Welfare Fee schedules for medical insurance Korea Ministry of Health and Welfare" (1998), Korea Ministry of Health and Welfare,
  13. "The political economy of health policy decision-making Korea's drug pricing policy reform", 11, pp.99~134 (2002)
  14. "Democratic transition and changes in Korean NGOs. Paper presented at the 1999 Seoul International Conference of NGOs", pp.12~ (1999), : CONGO, NGO[DOI]
  15. "NGOs movement without citizens Accessed on 12 September 2002" (2000)
  16. "People's Solidarity for Participatory Democracy of Korea Survey report of drug transactions People's Solidarity for Participatory Democracy of Korea" (1998), Unpublished document
  17. "Separation of prescription and dispensing Paper presented at the 2000 Fall Annual Meeting of The Korean Society of Health Policy and Administration" (2000)
  18. "The political character and feature in policy formation process A case study on separation of prescribing and dispensing drugs", 10, pp.23~55 (2001)
  19. "Proposal for reimbursement pricing for innovative drugs Korea Institute for Health and Social Welfare" (1999), Unpublished document
  20. "Health care policy agenda for 21st century" (1997), Health Care Reform Committee
  21. "Policy recommendations for health insurance drug pricing Korea Institute for Health and Social Affairs" (1998)
  22. "The multinational drug companies lobbying to increase prices of their products", Moonhwailbosa
  23. "Drug Pricing Commission of the National Health Insurance Final report of the task force for revising drug pricing policy Ministry of Health and Social Affairs" (2000), Unpublished document
  24. "Bureau of Health Insurance and Pension Report of policy measures for improving drug reimbursement pricing policy Ministry of Health and Welfare" (1999), Unpublished document
  25. "Korea Ministry of Health and Welfare Overview of health insurance system in Korea Korea Ministry of Health and Welfare" (2001), Unpublished document
  26. "Pharmaceutical price regulation in Korea Korea Institute for Health and Social Welfare" (2002)
  27. "Policy recommendations for the pharmaceutical industry in the 21st century" (2001), Unpublished document
  28. "The impact of the separation of prescription and dispensing on pharmaceutical industry", 64, pp.31~9 (2002)
  29. "The multinational drug companies making huge amount of profits in Korea", pp.26~ (2002), Kookminilbosa,
  30. "Problems of current drug pricing policy and its policy measures Paper presented at a public hearing for revising the drug pricing policy" (2001), Korea Hospital Association
  31. "Korea National Health Insurance Corporation. Major indicators of the national health insurance by year."
  32. "Comparative study of the utilization pattern under the national health insurance in Korea" (2002), Unpublished document
  33. "Korea Ministry of Planning and Budget Report on the measures for stabilizing the national health insurance budget Korea Ministry of Planning and Budget" (2002), Unpublished document
  34. "Korea Ministry of Health and Welfare Report on a survey of drug transactions Korea Ministry of Health and Welfare" (2002), Unpublished document
  35. "Pricing and reimbursement in Europe: A concise guide" (1996), PPR Communications

관련 논문AI추천

Configuring the New Topography of Korea’s Professional Interest Group Politics: An Investigation into the Declining Power of Organized Medicine in Health Politics김순양한국학중앙연구원 · Korea Journal2011 · 제51권 제1호The Political Dynamics of Policy Networks and Advocacy Coalitions in South Korea’s Healthcare Policymaking : The 20 Years of Debates to Inaugurate a Single‐Payer System김순양한국사회복지연구회 · 사회복지연구2011 · 제42권 제4호Democratization, Agenda-Setting, and the Regulation of Health-Care Professionals: Pharmaceutical Regulation in Korea임상헌(사)한국정치평론학회 · 정치와 공론2025 · 제36권 보험 약가제도에 대한 분석과 개선방안: 유인합치성 관점에서양채열한국국제경제학회 · 국제경제연구2002 · 제8권 제3호A Comparative Analysis of Corporatist Policymaking Coordination in Japan and Korea이주희한국사회과학협의회 · Korean Social Science Journal2006 · 제33권 제1호Reimbursement for drug sales even at the cost of collapsing a health care system in South Korea이종훈한국보건경제정책학회 · 보건경제와 정책연구2025 · 제31권 제2호

이 간행물의 다른 논문 (14건)

Efficacy of Oral Etidronate for Skeletal Disease in JapanTsuyoshi Takeda, Yoshihiro Sato, Jun Iwamotopp. 313-320Development of a Structural Model Explaining Medication Compliance of Persons with Schizophrenia민성길, 서미아pp. 331-340Limited Effect of CpG ODN in Preventing Type 1 Diabetes in NOD Mice조현철, 정춘희, 김미진, 심명숙, 신영구, 이병준, 박은섭, 김문규, 김수기pp. 341-346Effectiveness of Real-time Quantitative PCR Compare to Repeat (REP-)PCR for the Diagnosis of Charcot-Marie-Tooth Type 1A and Hereditary Neuropathy with Liability to Pressure Palsies최종락, 임종백, 선우일남, 이은경, 이창훈, 이운형pp. 347-352The Ocular Motility Disturbances in the Orbital Wall Fracture Patients유혜린, 윤영수, 이상훈pp. 359-367
원문 보기